Business Context and Reporting Period
This Form 8-K Current Report was filed by Sana Biotechnology, Inc. on October 4, 2024. The filing addresses significant changes in the company's executive leadership, specifically the resignation of the Chief Financial Officer and the subsequent appointment of interim financial officers.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Resignation: Nathan Hardy resigned as Executive Vice President, Chief Financial Officer, Treasurer, Principal Financial Officer (PFO), and Principal Accounting Officer (PAO), effective October 4, 2024.
- Interim Appointments:
- Steven D. Harr, M.D. (President and CEO) was appointed as Acting PFO.
- Susan Wyrick (Senior Vice President, Finance and Accounting) was appointed as Acting Chief Financial Officer, Treasurer, and PAO.
Compensation and Contingencies
In connection with her appointment to the interim role, Susan Wyrick received the following compensation adjustments:
- Monthly Stipend: An additional $5,000 per month for the duration of her interim service.
- Completion Bonus: A $25,000 bonus payable 60 days after the earlier of a new CFO's start date or June 1, 2025, contingent on continued service.
- Equity Grant: An award of 20,000 restricted stock units (RSUs) vesting in two equal installments on June 3, 2025, and December 3, 2025.
- Severance Provisions: If terminated without cause or resigning for good reason, Ms. Wyrick is entitled to six months of severance pay, six months of health insurance premiums, and acceleration of equity vesting that would have occurred within six months of separation.
No unusual items, risks, or forward-looking guidance regarding business operations were disclosed in this filing.
Investor Verification Checklist
- Verify the timeline for the recruitment of a permanent Chief Financial Officer to assess the duration of interim leadership.
- Review the impact of the $5,000 monthly stipend and $25,000 bonus on the company's near-term cash burn rate.
- Confirm the vesting schedule and potential acceleration triggers for the 20,000 RSUs granted to Ms. Wyrick.
- Monitor future filings for any disclosure regarding the reasons for Nathan Hardy's resignation.